Kahalalide compounds are peptides that are isolated from a Hawaiian herbivorous marine species of mollusc, Elysia rufescens, and its diet, the green alga Bryopsis sp. Kahalalide F and its synthetic analogues are the most promising compounds of the Kahalalide family because they show anti-tumoral activity. Linear solidphase syntheses of Kahalalide F have been reported. Here we describe several new improved synthetic routes based on convergent approaches with distinct orthogonal protection schemes for the preparation of Kahaladide analogues. These strategies allow a better control and characterization of the intermediates because more reactions are performed in solution. Five derivatives of Kahalalide F were synthesized using several convergent approaches.
Linear solid-phase syntheses of Kahalalides involving cyclization and final deprotection performed in solution have been described. 8, 11 However, synthetic routes for Kahalalide compounds are still required. Here we report several new convergent strategies for the synthesis of Kahalalide F derivatives. Convergent strategies are defined as those in which peptide fragments are coupled to give the desired target molecule. 12,13,14, 15 The condensation of peptide fragments should lead to fewer problems in the isolation and purification of intermediates. The difference between the condensation product desired and the segments themselves, in terms of molecular size and chemical nature, should be sufficiently pronounced so as to permit their separation relatively easily. Several orthogonal protecting schemes have been used in these strategies. 16 Although solid-phase strategies are crucial for peptide synthesis, 12b, 17, 18, 19, 20 the method of choice for a convergent strategy involves a combination of solid-phase and solution chemistries. Thus, protected peptides are prepared in solid-phase and then combined in solution. 21,22 a Paradigm of this strategy is the large-scale commercial production of enfuvitide (T-20 or Fuzeon), a 36-amino acid peptide.
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Results and Discussion
To render Kahalalide F a 14-building block peptide [13 amino acids and the methylhexanoic acid], the most convenient synthetic strategy involves dividing the peptide in two fragments, the N-terminal and the fragment containing the cycle. Fragment composition can be modified in order to optimize condensation yields and minimize side reactions, such as epimerization.
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N-Component KF Scheme 1. Convergent strategy for the synthesis of Kahalalide F analogues. AAA, BBB, CCC, DDD, and EEE are amino acid residues.
The preparation of the N-Component requires cyclization in solution and therefore the N-protection should also be kept during the cleavage of the lineal fragment from the resin.
Solid-phase synthesis of protected peptides requires a resin that facilitates the release of the peptide without removing the side-chain protecting groups, which are removed as the last step of the synthesis. 12a,13,14 In this regard, the tBu-based protecting groups are highly convenient because they are removed with high concentrations of trifluoroacetic acid (TFA) in the presence of scavengers and are stable to piperidine, used to remove the α-amino protecting group, and to low concentrations of TFA. The super-acid-labile chlorotrityl chloride polystyrene (CTC, Barlos, ) resin allows the release of peptides with 1-2 % of TFA in CH 2 Cl 2 or even with trifluoroethanol or hexafluoroacetone solutions. 24 An additional advantage of the CTC resin is that its hindered structure minimizes the formation of the diketopiperazines (DKP) during removal of the temporal protecting group of the second amino acid. 25, 26 General Strategies: Three sets of fragments were prepared. 
Scheme 3. N-Components synthesized
A priori, the main advantage of strategy 1 is that the hardly racemizable Pro is the C-terminal amino acid for the C-Component. In contrast, the advantage of strategies 2 and 3 is that the N-Component does not contain any side-chain protecting group and therefore a level of protecting groups can be avoided for these fragments.
All fragments were synthesized on the CTC-resin, starting with a limited incorporation of the first 9-fluorenylmethoxycarbonyl (Fmoc)-amino acid in the presence of N,N-diisopropylethylamine (DIEA). 27 The remaining resin chloride functions were capped with methanol (MeOH) to prevent the formation of tertiary amines after treatment with the piperidine used to remove the Fmoc group. 28 The Fmoc-protecting group was removed with piperidine−N,N-dimethylformamide (DMF) (1:4) and the peptide chain was elongated with N,N'-diisopropylcarbodiimide (DIPCDI) and 1-hydroxybenzotriazole (HOBt) as coupling reagents. Finally, the peptides were cleaved from the resin with TFA−CH 2 Cl 2 (1:99), characterized by HPLC and ESMS, and purified by semi-preparative HPLC when necessary.
Synthesis of the N-Components:
The ZDhb moiety was incorporated through the dipeptide allyloxycarbonyl (Alloc)-Phe-ZDhb-OH, wich is much faster than incorporating sequentially Thr and Phe and performing the dehydratation of Thr to ZDhb on solid phase. 8, 11 Four synthetic strategies were used to prepare the three distinct N-Components (Scheme 4). All the strategies are based on the solid-phase synthesis of a branched peptide using a tri-or tetra-orthogonal protecting scheme and subsequent cyclization and deprotection of the N-terminal function in solution. Strategy 1, which produces the N-Component 1, follows the procedure previously described 8, 11 and starts with the incorporation of Fmoc-D-Val-OH on the CTC resin, followed by elongation until the D-aIle 7 , esterification of the β- ZDhb does not show chirality and therefore no epimerization occurred during the cyclization step, which is the most prone for inducing racemization.
In strategies 3 and 4, and as the N-Components 2 and 3 did not contain any side-chain protecting group, the Boc group was used as N α -amino protecting group of the N-terminal residue (DaIle 7 in strategy 3 and DaThr in the 4). In addition to the full stability of the lactone bond to the conditions (TFA) used to remove that protecting group, the main advantages associated with the use of the Boc group were that the reagent to remove this group as well as the side-products formed were volatile and therefore could be removed by simple evaporation. PyAOP gave the best results in terms of yields and the absence of side-products in the HPLC chromatograms (Table 1) . Phosphonium derivatives such as PyAOP are more convenient for slow couplings compared with aminium/uronium reagents such as HATU, since the latter can terminate the peptide chain through a guanidination reaction. 34 Furthermore, PyAOP contains HOAt, which is the most reactive benzotriazole. 
Condensation of linear and cyclic fragments:
Conclusions
Here we developed several convergent strategies for the synthesis of the analogues of the antitumor peptide Kahalalide F. The best approaches were those in which the C-terminal amino acid of the C-Component is DPro because it avoids epimerization during the coupling of the fragment in solution. The choice of the semipermanent protecting group for the N α -amino of Orn-protecting groups requires additional discussion. Thus, the use of the less common groups, pNZ, and Alloc, which assure total stability of the lactone, implies the concourse of metallic cations or metals, which may demand a purification step before the final fragment coupling. Furthermore, the Fmoc group requires fine-tuning of the experimental process, which can be detrimental for the development of a large scale process in which conditions may be more difficult to control.
The use of the N-Component prepared by strategy 2 (Scheme 4) shows several advantages because it allows the preparation of Kahalalide F without risk of epimerization during cyclization and uses lower amounts of the precious Alloc-Phe-ZDhb-OH.
Experimental Section
General Procedures. Cl-TrtCl-resin, Protected Fmoc-amino acid derivatives, HOBt, HOAt were purchased from different sources as well as DIPEA, DIPCDI, EDC . HCl, piperidine, TFA, DMF, MeCN (HPLC grade) and CH 2 Cl 2 . All commercial reagents and solvents were used as received with the exception of DCM, which was passed through an alumina column to remove acidic contaminants.
pNZ-Orn(Boc)-OH was prepared as described previously 29 and Alloc-amino acids as essentially described [
The Fmoc group of the peptide resin (2) 
[Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-O-TrtCl-resin][Alloc-Phe-ZDhb-Val&] (4):
The 
[Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-OH][H-Phe-ZDhb-Val&] (5):
The Alloc group of the peptide resin (4) 
Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (6):
The protected peptide (5) 
H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1):
The protected peptide (6) 
N-Component 1: H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& from pNZ-
Orn(Boc)-OH:
pNZ-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (7):
The synthesis was performed in the same way as for compound 6, but Fmoc-Orn(Boc)-OH was replaced by
pNZ-Orn(Boc)-OH. H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1)
The protected peptide (14.7 mg, 12.8 µmol) was dissolved in 1. 
[Alloc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-OH][H-Val&] (9):
Fmoc 
H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1):
Peptide 10 was dissolved in 10 mL of CH 2 Cl 2 , then Pd( showed completion of the reaction. HPLC showed that the crude obtained after evaporation had a purity of > 75 %.
The crude product was purified by HPLC (Symmetry C8 5 µm, 30x 100 mm), linear gradient of MeCN (+0.05% TFA) in water (+0.05% TFA) (30% to 100% in 15 min), 20 mL/h, detection at 220 nm, to give the protected Kahalalide F (6.9 mg, 4.2 µmol, 49% yield). Alloc-Phe-ZDhb-OH (666 mg, 2 mmol, 4 equiv) and HOAt (273 mg, 2 mmol, 4 equiv) were dissolved in DMF (1.25 mL) and added to peptidyl-resin. DIPCDI (310 µL, 2 mmol, 4 equiv) was then added and the mixture was stirred for 5 h; at which point the HPLC showed completion of reaction (R t 7.09 min, Column A). 
C-Component
Phe-ZDhb-Val&
The synthesis was carried out as described for the stepwise synthesis of Kahalide except that FmocOrn(Boc)-OH is replaced by Fmoc-D-Orn(Boc)-OH. 8 The product was characterized by HPLC (R t 9.89 min, 
N-Component
